Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Myriad Genetics Inc (NQ: MYGN ) 28.47 UNCHANGED Streaming Delayed Price Updated: 4:00 PM EDT, Sep 18, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 0 Open 28.47 Bid (Size) 27.00 (3) Ask (Size) 45.26 (1) Prev. Close 28.47 Today's Range 28.47 - 28.47 52wk Range 13.82 - 29.30 Shares Outstanding 90,900,000 Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Myriad Genetics to Share New Data Highlighting Genetic Testing Advancements at 2024 National Society of Genetic Counselors Annual Conference September 18, 2024 MyRisk®, FirstGene®, Prequel®, and Foresight® studies among 10 datasets to be shared by Myriad From Myriad Genetics, Inc. Via GlobeNewswire G-III Apparel Posts Upbeat Results, Joins NIO, Yext, Shoe Carnival And Other Big Stocks Moving Higher On Thursday September 05, 2024 Via Benzinga Performance YTD +49.84% +49.84% 1 Month +0.74% +0.74% 3 Month +19.62% +19.62% 6 Month +28.01% +28.01% 1 Year +64.00% +64.00% More News Read More Myriad Genetics to Host Investor Event on October 9, 2024 September 05, 2024 From Myriad Genetics, Inc. Via GlobeNewswire Myriad Genetics Stock: A Deep Dive Into Analyst Perspectives (5 Ratings) August 13, 2024 Via Benzinga Key Takeaways From Myriad Genetics Analyst Ratings June 27, 2024 Via Benzinga Myriad Genetics to Participate in Two Upcoming Investor Healthcare Conferences August 21, 2024 From Myriad Genetics, Inc. Via GlobeNewswire Thermo Fisher Scientific Stock Sees RS Rating Jump To 81 August 13, 2024 Via Investor's Business Daily MYGN Stock Earnings: Myriad Genetics Beats EPS, Beats Revenue for Q2 2024 August 06, 2024 Via InvestorPlace Myriad Genetics Reports Strong Second Quarter 2024 Financial Results, including 15% Revenue Growth Year-Over-Year; Raises 2024 Financial Guidance and Long-Term Revenue Growth Target to 12% August 06, 2024 From Myriad Genetics, Inc. Via GlobeNewswire Myriad Genetics Advances International Reorganization and Completes Sale of EndoPredict Business to Eurobio Scientific August 01, 2024 From Myriad Genetics, Inc. Via GlobeNewswire Myriad Genetics Appoints Jennifer Fox as Chief Legal Officer July 31, 2024 From Myriad Genetics, Inc. Via GlobeNewswire Avantor Stock Earns 84 RS Rating July 30, 2024 Via Investor's Business Daily Myriad Genetics to Release Second Quarter 2024 Financial Results on August 6, 2024 July 30, 2024 From Myriad Genetics, Inc. Via GlobeNewswire What We Don’t Know Can Hurt: New Cancer Risk Survey from Myriad Genetics Reveals Serious Knowledge Gaps About Breast Density and Cancer Risk July 17, 2024 From Myriad Genetics, Inc. Via GlobeNewswire Myriad Genetics and Personalis Cross-License Foundational MRD Intellectual Property to Broaden Patient Access to Testing July 11, 2024 From Myriad Genetics, Inc. Via GlobeNewswire Myriad Genetics Announces Second Foundational Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date July 09, 2024 From Myriad Genetics, Inc. Via GlobeNewswire The 3 Best Gene Editing Stocks to Buy in July 2024 July 08, 2024 Via InvestorPlace Myriad Genetics Earns 2024 Great Place To Work® Certification™ July 02, 2024 From Myriad Genetics, Inc. Via GlobeNewswire Survey Suggests Increased Attention on Mental Health Warranted in the Run-Up to the Election June 24, 2024 From Myriad Genetics, Inc. Via GlobeNewswire Myriad Genetics Sees Stock Surge with Hereditary Cancer Tests June 18, 2024 Via MarketBeat Myriad Genetics Collaborates with GSK to Improve Access to HRD Testing in 9 Countries June 11, 2024 From Myriad Genetics, Inc. Via GlobeNewswire Myriad Genetics Launches New Universal Plus Panel for Foresight® Carrier Screen June 04, 2024 From Myriad Genetics, Inc. Via GlobeNewswire Genetics in Medicine Publishes Myriad Genetics Patient-Outcomes Study Validating RiskScore® as a Clinical Breast Cancer Risk Assessment Tool June 03, 2024 From Myriad Genetics, Inc. Via GlobeNewswire QIAGEN and Myriad Genetics develop distributable homologous recombination deficiency test for global research and companion diagnostics applications May 30, 2024 From Myriad Genetics, Inc. Via GlobeNewswire Myriad Genetics Showcases New Research and Product Innovations Advancing Cancer Care at 2024 ASCO® Annual Meeting May 23, 2024 From Myriad Genetics, Inc. Via GlobeNewswire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
